Redox signaling in ischemic postconditioning protection involves PKCε and Erk1/2 pathways and converges indirectly in Nrf2 activation-Reference-Cited by-同舟云学术

Redox signaling in ischemic postconditioning protection involves PKCε and Erk1/2 pathways and converges indirectly in Nrf2 activation

Published:2019-12 Issue: Volume:64 Page:109417
ISSN:0898-6568
Container-title:Cellular Signalling
language:en
Short-container-title:Cellular Signalling

Author:

Díaz-Ruíz Jorge-Luis,Macías-López Arturo,Alcalá-Vargas Francisco,Guevara-Chávez José-Guadalupe,Mejía-Uribe Aída,Silva-Palacios Alejandro,Zúñiga-Muñoz Alejandra,Zazueta Cecilia,Buelna-Chontal Mabel^ORCID

Funder

National Institute of Cardiology, I.Ch

Publisher

Elsevier BV

Subject

Cell Biology

Reference63 articles.

1. Metabolic adaptation to a disruption in oxygen supply during myocardial ischemia and reperfusion is underpinned by temporal and quantitative changes in the cardiac proteome;Li;J. Proteome Res.,2012

2. Effect of cyclosporine on left ventricular remodeling after reperfused myocardial infarction;Mewton;J. Am. Coll. Cardiol.,2010

3. The mitochondrial permeability transition pore and its role in myocardial ischemia reperfusion injury;Ong;J. Mol. Cell. Cardiol.,2015

4. Myocardial ischemia-reperfusion injury: a neglected therapeutic target;Hausenloy;J. Clin. Invest.,2013

5. Redox balance and cardioprotection;Tullio;Basic Res. Cardiol.,2013

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Novel Postconditioning Approach Attenuates Myocardial Ischaemia-Reperfusion Injury in Rats;Reviews in Cardiovascular Medicine;2024-02-18

2. Ischemia-reperfusion injury: molecular mechanisms and therapeutic targets;Signal Transduction and Targeted Therapy;2024-01-08

3. EP1 activation inhibits doxorubicin-cardiomyocyte ferroptosis via Nrf2;Redox Biology;2023-09

4. The RISK pathway leading to mitochondria and cardioprotection: how everything started;Basic Research in Cardiology;2023-05-26

5. Challenges facing the clinical translation of cardioprotection: 35 years after the discovery of ischemic preconditioning;Vascular Pharmacology;2022-06